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Background: In the present study, we tested a 50% ethanolic extract of Orthosiphon stamineus plants and its
isolated bioactive compound with respect to their α-glucosidase and α-amylase inhibitory activities.
Methods: Bioactive flavonoid sinensetin was isolated from 50% ethanolic extract of Orthosiphon stamineus. The
structure of this pure compound was determined on the NMR data and the α-glucosidase and α-amylase inhibitory
activities of isolated sinensetin and 50% ethanolic extract of Orthosiphon stamineus were evaluated.
Results: In vitro studies of a 50% ethanolic extract of O. stamineus and the isolated sinensetin compound showed
inhibitory activity on α-glucosidase (IC50: 4.63 and 0.66 mg/ml, respectively) and α-amylase (IC50: 36.70 mg/ml and
1.13 mg/ml, respectively). Inhibition of these enzymes provides a strong biochemical basis for the management of
type 2 diabetes via the control of glucose absorption.
Conclusion: Alpha-glucosidase and α-amylase inhibition could the mechanisms through which the 50% ethanolic
extract of O. stamineus and sinensetin exert their antidiabetic activity, indicating that it could have potential use in
the management of non-insulin-dependent diabetes.Background
The number of diabetic patients is rapidly rising in most
parts of the world, especially in developing countries
such as Thailand, India and Indonesia. In general, the
control of blood glucose concentrations near the normal
range is mainly based on the use of oral hypoglycaemic/
antihyperglycaemic agents and insulin. However, all of
these treatments have limited efficacy and are associated
with undesirable side effects [1-3], leading to increasing
interest in the use of medicinal plants for the alternative
management of type 2 diabetes mellitus. The control of
postprandial plasma glucose levels is critical in the early
treatment of diabetes mellitus and for reducing chronic
vascular complications [4]. A sudden increase in blood* Correspondence: aliali692002@yahoo.com; yammunfei@yahoo.com
1School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang
11800, Malaysia
Full list of author information is available at the end of the article
© 2012 Mohamed et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumglucose levels, which causes hyperglycaemia in type 2
diabetes patients, occurs due to the hydrolysis of starch
by pancreatic α-amylase and the uptake of glucose by in-
testinal α-glucosidases [5]. An effective strategy for type
2 diabetes management is the strong inhibition of intes-
tinal α-glucosidases and the mild inhibition of pancreatic
α-amylase [6]. One therapeutic approach for reducing
postprandial hyperglycaemia in patients with diabetes
mellitus is preventing the absorption of carbohydrates
after food uptake. Only monosaccharides, such as glu-
cose and fructose, can be transported out of the intes-
tinal lumen into the bloodstream. Complex starches,
oligosaccharides and disaccharides must be broken down
into individual monosaccharides before they are
absorbed in the duodenum and upper jejunum. This di-
gestion is facilitated by enteric enzymes, including pan-
creatic α-amylase and α-glucosidases attached to the
brush border of intestinal cells.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion as alternative medicines in recent years in Malay-
sia and are sold as dietary supplements. One of the
local herbs, scientifically known as Orthosiphon stami-
neus Benth (Lamiaceae) or locally called misai kucing,
has attracted much attention for research purposes.
Orthosiphon stamineus is also found in other countries
such as Thailand, Indonesia and Europe. In these
countries, misai kucing is also known as yaa nuat
maeo, rau meo or cay bac (Thailand), kumis kucing or
remujung (Indonesia), moustaches de chat (French)
and Java tea (European) [7]. It is widely used for the
treatment of many diseases, especially those affecting
the urinary tract, diabetes mellitus, hypertension,
rheumatism, tonsillitis and menstrual disorders. The
methanolic extracts of this plant have shown inhibitory
activity on nitric oxide production in macrophage-like
cells [8,9]. Several classes of compounds have been
identified in this plant, including flavonoids, terpe-
noids, saponins, hexoses, organic acids, caffeic acid
derivatives, chromene and myo-inositol [10-14]. The
most important components of O. stamineus leaves are
the polyphenols, the polymethoxylated flavonoids:
sinensetin and eupatorine, etc., and the caffeic acid
derivatives: rosmarinic acid, cichoric acid and caffeic
acid, etc. [14]. Intestinal glycosidase enzymes play an
important role in carbohydrate digestion and absorp-
tion. Therefore, an inhibitor of intestinal glucosidase
could be expected to retard carbohydrate digestion and
absorption. One reasonable method of controlling
these carbohydrate–dependent diseases would be to
limit intestinal carbohydrate digestion. It has been
recognized that α-glucosidase inhibitors can be used to
prevent certain disorders such as diabetes, obesity,
hyperlipidaemia and hyperlipoproteinaemia.
We previously reported that the O. stamineus was able
to reduced blood glucose in STZ-induced diabetic rat. In
the same study we reported sinensetin, eupatorin and 30-
hydroxy-5,6,7,40-tetramethoxyflavone are present in O.
stamineus [15-17]. Although many O. stamineus have
been per-formed, a clear antidiabetic mechanism of ac-
tion for this plant has not yet been established. To the
best of our knowledge there have been no previous
reports on the in vitro inhibitory activity of the O. stami-
neus plant on α-glucosidase or α-amylase and this in-
hibitory effect could be one of the mechanisms of action
of anti-diabetic effect of O. stamineus. The aim of the
present study was to evaluate the in vitro effects of a
50% ethanolic extract of O. stamineus and its identified
compound sinensetin on α-glucosidase and α-amylase
enzyme inhibition compared to their previously reported
antihyperglycaemic effects in normal and STZ-induced
diabetic rats [15] in order to contribute to the under-
standing of their mechanisms of action.Methods
Plant materials and preparation of the samples
Leaves of Orthosiphon stamineus were obtained from
Kepala Batas, Pulau Pinang Malaysia. The plant was
identified by the School of Biological Sciences, Universiti
Sains Malaysia, and a voucher specimen (10810) was
deposited at the Herbarium of the School of Biological
Sciences, Universiti Sains Malaysia. The dried leaves were
powdered using a milling machine and were extracted
with 50% (v/v) ethanol using the maceration method
(200 g dried leaves in 2 l of 50% ethanol at 55°C for 24 h;
two cycles) for 7 days. The extracts were filtered and
concentrated at 60°C using a rotary evaporator (Buchi
Labortechnik, Flawil, Switzerland). Finally, the concen-
trated extract was freeze-dried (Labconco Corporation,
Kansas City, MO, USA) to yield 10.3% dry powder.
HPLC study of the 50% ethanolic extract of O. stamineus
High-performance liquid chromatography (HPLC)
analysis was performed using a Shimadzu-LC system (Shi-
madzu, Japan) equipped with a CBM-20A controller, LC-
20AT pump, DGU-20A5 degasser, SIL-20A auto-sampler,
SPD-20AV detector and a CTO-10ASvp column oven.
Chromatographic separations were achieved using an
Agilent Eclipse Plus C18 (250 × 4.6 mm i.d.; 5 μm). A
Zorbax guard fittings kit packed with a replaceable
Eclipse Plus C18 Guard column (12.5 × 4.6 mm i.d.; 5
μm) was used to protect the analytical column. A
reverse-phase HPLC assay was carried out using an iso-
cratic system at a flow rate of 1 ml/min, a column
temperature of 25°C and a mobile phase of acetonitrile,
isopropyl alcohol and 0.02 M phosphate buffer
(NaH2PO4) (30:15:55 v/v) with the pH adjusted to pH
3.5 using 85% phosphoric acid. The UV detection was
set at 340 nm. The injection volume was 20 μl of solu-
tion. The total run time was less than 20 min for each
injection. Data were acquired and processed using LC-
Solution Software. The peaks were detected at 340 nm
and identified using standard substances, namely, sinen-
setin, eupatorin and 30-hydroxy-5,6,7,40-tetramethoxyfla-
vone. The 50% ethanol extract of O. stamineus at 10
mg/ml was used as a stock solution. The stock solution
was then diluted with the mobile phase to 1 mg/ml as
the sample solution. The total amounts of 30hydroxy-
5,6,7,40-tetramethoxyflavone, sinensetin and eupatorin
(purchase from Indofine Chemical Company, NJ, USA)
in the 50% ethanol extract of O. stamineus were quanti-
fied using developed HPLC method (n = 3). The contents
of these three compounds were expressed as percentages
of the dried extract [18].
Isolation of the compounds
The 50% ethanolic extract of O. Stamineus was sepa-
rated into ethyl acetate, butanol and water-soluble
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caemic activity was separated via silica-gel column chro-
matography to give two sub-fractions: namely ESF-1
(non-active) and ESF-2 (active) (ethyl acetate fraction
and sub-fraction ESF-2 were active in antihyperglycae-
mic effect, unpublished result). The ESF-2 was fraction
was then subjected to silica gel chromatography for bio-
active compound isolation [19]. Isolated compound was
subjected NMR study [19]. All the spectroscopic data in
good agreement with Yam et al, 2010, it can be con-
cluded that the isolated compound was sinensetin [19].
In vitro α-glucosidase inhibition study
The α-glucosidase was assayed using a method modified
by Apostolidis et al [20], where a 50% ethanolic extract of
O. stameinus (62.5, 31.25, 15.6, 7.8, 3.9, and 1.95 mg/ml in
dimethylsulphoxide:distilled water (1:1) solution) and
sinensetin (2.5, 1.25, 0.625, and 0.3125 mg/ml in metha-
nol) were prepared. Then, 50 μl of 50% ethanolic extract
of O. stameinus or sinensetin solution will mixed well with
100 μl of 0.1 M phosphate buffer (pH 6.9) containing α-
glucosidase (Sigma, St. Louis, USA) solution (1.0 U/ml)
and the mixture were then incubated in 96-well plates at
25°C for 10 min. After pre-incubation, 50 μl of 5 mM p-
nitrophenyl-α-D-glucopyranoside (Sigma, St. Louis, USA)
solution in 0.1 M phosphate buffer (pH 6.9) was added to
each well at timed intervals. The reaction mixtures were
incubated at 25°C for 5 min. Before and after incubation
absorbance readings were recorded at 405 nm using a
micro-plate reader (Thermomax, Molecular device Co.,
Virginia, USA) and compared to a control which con-
tained 50 μl of the buffer solution instead of the extract.
The experiments were performed in triplicate and the α-
glucosidase inhibitory activity was expressed as percentage
inhibition. Acarbose (Bayer Pharmaceuticals, Leverkusen,
Germany) was prepared in distilled water at 10, 5, 2.5 and
1.25 mg/ml were made and used as positive controls.
Alpha-amylase inhibition assay
The inhibition of α-amylase was determined using an
assay modified from the Worthington Enzyme Manual
[21], where a 50% ethanolic extract of O. stameinus (62.5,
31.25, 15.6, 7.8, 3.9, and 1.95 mg/ml in dimethylsulphox-
ide:distilled water (1:1) solution) and sinensetin (2.5, 1.25,
0.625, and 0.3125 mg/ml in methanol) were prepared. A
total of 500 μl of each concentration of extract and sinen-
setin mixed with and 500 μl of 0.02 M sodium phosphate
buffer (pH 6.9) containing α-amylase (Sigma, St. Louis,
USA) solution (0.5 mg/ml) and incubated at 25°C for 10
min. After pre-incubation, 500 μl of a 1% starch solution
in 0.02 M sodium phosphate buffer (pH 6.9) was added to
each tube at timed intervals. The reaction mixtures were
then incubated at 25°C for 10 min. The reaction was
stopped with 1.0 ml of dinitrosalicylic acid (Sigma, St.Louis, USA) colour reagent. The test tubes were then
incubated in a boiling water bath for 5 min and cooled to
room temperature. The reaction mixture was then diluted
after adding 15 ml of distilled water, and the absorbance
was measured at 540 nm using a micro-plate reader
(Thermomax, Molecular device Co., Virginia, USA). The
experiments were performed in duplicate and the absorb-
ance of sample blanks (buffer instead of enzyme solution)
and a control (buffer in place of sample extract) were also
recorded. The absorbance of the final extract was obtained
by subtracting its corresponding sample blank reading.
Sinensitin was dissolved in methanol and serial dilutions
of 2.5, 1.25, 0.62 and 0.31 mg/ml were prepared. Acarbose
was prepared in distilled water at 10, 5, 2.5 and 1.25 mg/
ml were made and used as positive controls.
Statistical analysis
All the data were showed as mean ± SD and statistical
analysis were performed using one-way analysis of vari-
ance (ANOVA) followed by Tukey multiple comparison




The HPLC results showed that the percentages of
30hydroxy-5,6,7,40-tetramethoxyflavone, sinensetin and
eupatorin in the 50% ethanolic extract of O. Stami-
neus were 1.0150 ± 0.0007%, 3.7642 ± 0.0188%, and
3.0315 ± 0.0252%, respectively (Figure 1).
In vitro α-glucosidase inhibition study
The in vitro α-glucosidase inhibition study showed that
both the 50% ethanol extract of O. stamineus and sinen-
setin inhibited α-glucosidase. The percentage inhibition
at the α-glucosidase concentrations of 62.5, 31.25, 15.6,
7.8, 3.9 and 1.95 mg/ml by the 50% ethanol extract of O.
stamineus showed a concentration-dependent reduction.
The highest concentration of 62.5 mg/ml showed a max-
imum inhibition of nearly 81.4%, while the lowest con-
centration of 1.95 mg/ml showed a minimum inhibition
of nearly 16.2% (Figure 2(b)). Sinensetin showed strong
inhibition percentages ranging from 89.0–32.0% for α-
glucosidase concentrations ranging from 2.5–0.31 mg/
ml (Figure 2(c)). The 50% ethanolic extract of O. stami-
neus was less potent in inhibiting α-glucosidase com-
pared to acarbose and sinensetin. Acarbose was found to
be the most active with a half maximal inhibitory con-
centration (IC50) of 1.93 ± 0.281 mg/ml. The IC50 values
of the 50% ethanolic extract of O. stamineus and sinen-
setin were 4.63 ± 0.413 and 0.66 ± 0.025 mg/ml, respect-
ively (Figure 2(d)). IC50 values of sinensetin was
significantly lower than acarbose and 50% ethanolic ex-
tract of O. stamineus at P < 0.01.
Figure 1 HPLC chromatogram of standard markers. Peaks: (a) Standard TMF (30-hydroxy-5,6,7,40-tetramethoxyflavone), SEN (sinensetin)
and EUP (eupatorin). (b): HPLC chromatogram of 50% ethanolic extract of O. stamineus.
Figure 2 Percentage inhibition of acarbose (a), 50% ethanol extract of O. stamineus (b) and sinensetin (c) and IC50 of treatment groups
(d) on α-glucosidase enzyme in vitro. Result represented as mean ± S.D. of percent enzyme activity.
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The 50% ethanolic extract of O. stamineus showed a
weak inhibition of the α-amylase enzyme. Figure 3
shows the percentage inhibition values of the 50% etha-
nolic extract of O. stamineus, sinensetin and acarbose
against porcine α-amylase. The maximum inhibition was
69.2% at a concentration of 62.5 mg/ml (Figure 3(b)).
Sinensetin produced a maximum inhibition of 85.8% at
2.5 mg/ml (Figure 3(c)). Acarbose showed a maximum
percentage inhibition of 98.0% at 10 mg/ml (Figure 3(a)).
The IC50 values for the 50% ethanolic extract of O. sta-
mineus, acarbose and sinensetin were 36.70 ± 0.546 mg/
ml, 4.89 ± 0.397 mg/ml and 1.13 ± 0.026 mg/ml, respect-
ively (Figure 3(d)). IC50 values of sinensetin was signifi-
cantly lower than acarbose and 50% ethanolic extract of
O. stamineus at P < 0.05 and P < 0.001, respectively.
Discussion
Diabetes mellitus is a metabolic disorder of multiple
aetiologies that is characterized by chronic hyperglycaemia
with disturbed carbohydrate, fat and protein metabolism
resulting from defects in insulin secretion, insulin actions
or both [22]. One therapeutic approach for treating dia-
betes is to decrease post-prandial hyperglycaemia. This is
done by hindering the absorption of glucose through
inhibition of the carbohydrate hydrolysing enzymes, α-
amylase and α-glucosidase, in the digestive tract. Inhibi-
tors of these enzymes delay carbohydrate digestion,
causing a reduction in the rate of glucose absorption andFigure 3 Percentage inhibition of acarbose (a), 50% ethanol extract o
(d) on α-amylase enzyme in vitro (d)Result represented as mean ± S.Dconsequently blunting the post-prandial increase of
plasma glucose [23]. Examples of such inhibitors in clin-
ical use are acarbose, miglitol and voglibose [24]. The
post-prandial lowering of blood glucose by α-glucosidase
inhibitors such as miglitol and acarbose after a starch load
is well established. The mechanism of action is through
the inhibition of the last step in carbohydrate digestion,
namely the conversion of disaccharide to monosaccharide
(glucose) and a consequent decrease in the rate of entry of
glucose into the systemic circulation [25].
Present studies showed that O. stamineus extract sig-
nificantly reduced plasma glucose concentration in both
normal and diabetic rats [26,27]. In addition, O. stami-
neus extract also potentiated glucose-induced insulin se-
cretion [28] may be beneficial to patients with diabetes
mellitus who have a defect in the insulinotropic response
to glucose. Although there are citations of antihypergly-
caemic and antidiabetic [26,27] activities of O. stamineus
extracts based on free radical scavenging activity and in
part on increased glucose metabolism, there are no pre-
vious reports, at least to the best of our knowledge,
about the inhibitory activity of this plant extract on
in vitro α-glucosidase and α-amylase.
The present in vitro studies demonstrated an appre-
ciable inhibitory activity of 50% ethanolic extracts of O.
stamineus and sinensetin on α-glucosidase and α-amylase.
Orthosiphon stamineus showed similar inhibitory effects
on α-glucosidase and α-amylase. The IC50 values showed
that the 50% ethanolic extract of O. stamineus andf O. stamineus (b) and sinensetin (c) and IC50 of treatment groups
. of percent enzyme activity.
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glucosidase and α-amylase enzymes. Alpha-glucosidase
and α-amylase inhibition could potentially be used as an
effective therapy for post-prandial hyperglycaemia linked
to type 2 diabetes. This approach has fewer side effects,
such as abdominal distention, meteorism and possibly
diarrhoea resulting from the abnormal bacterial fermenta-
tion of undigested carbohydrates in the colon, as normally
seen when potent α-glucosidase inhibitors like acarbose
and voglibiose are used. The goals of the in vitro α-
glucosidase and α-amylase inhibitory studies were to pro-
vide in vitro evidence for the potential inhibition of α-
glucosidase and α-amylase and to generate a stronger bio-
chemical rationale for further studies on 50% ethanolic
extracts of O. stamineus leaves.
Present study also found active anti-diabetic O. stami-
neus extract contain of high phenolic compound and fla-
vonoid [27]. Several other classes of chemicals also have
been found in O. stamineus that are rich terpenoids, caf-
feic acid derivatives and chromene [10,13,14]. Among
these phytochemical groups caffeic acid and phenolic
compound have been reported to increase glucose up-
take in rat myocytes [28].
It is thought that one or more different compounds
(e.g. sinensetin) that were present in the extracts play an
important role in the inhibition of α-glucosidase and
α-amylase. Furthermore, some of the compounds found
in this extract (phenolics, flavonoids and their glyco-
sides) were mentioned by Tadera et al [29] and Kwon et
al [30] as being effective inhibitors of α-glucosidase.
Based on the results presented in this study, it can be
concluded that a 50% ethanolic extract of O. stamineus
exerts an inhibitory effect on α-glucosidase and α-amyl-
ase. These results further support the traditional use of
plants in medicine based on their inhibitory activity of
glucose absorption in the gut.
It is thought that one or more different compounds
(e.g. sinensetin) that were present in the extracts play
an important role in the inhibition of α-glucosidase
and α-amylase. Furthermore, some of the compounds
found in this extract (phenolics, flavonoids and their
glycosides) were mentioned by Tadera et al [29] and
Kwon et al [30] as being effective inhibitors of α-glucosidase.
Conclusion
Based on the results presented in this study, it can be
concluded that a 50% ethanolic extract of O. stamineus
exerts an inhibitory effect on α-glucosidase and α-amyl-
ase. These results further support the traditional use of
plants in medicine based on their inhibitory activity of
glucose absorption in the gut.
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